Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches

May 11 2017

• By Emily Hayes

Cholesterol plaque in artery

Related Content

Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund

May 03 2017

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Mar 18 2017

Sanofi/Regeneron Get Reprieve: Praluent Can Stay On Market For Now

Feb 09 2017

Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

Mar 20 2017

Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?

Apr 21 2017

Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance

Apr 27 2017

Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings

Apr 26 2017

Sanofi Scouting For Cancer Deals, Diabetes Drugs Miss In 1Q

Apr 28 2017

Related Companies

Amgen, Inc.

Sanofi

Pfizer Inc.

Halozyme Therapeutics, Inc.

Alnylam Pharmaceuticals Inc.

The Medicines Company

Merck & Co., Inc.

Additional Topics

Market Access Reimbursement Pricing Strategies Commercial Cardiovascular BioPharmaceutical

More from Cardiovascular

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window